Skip to content

Vibration for Muscle Spasms After Spinal Cord Injury

Closed Loop Control of Vibration for Muscular Spasms After Human Spinal Cord Injury: Efficacy and Mechanism

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03598504
Enrollment
198
Registered
2018-07-26
Start date
2019-07-16
Completion date
2023-06-30
Last updated
2021-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Keywords

SCI, Spasms, Vibration

Brief summary

This study uses closed-loop control of tendon vibration to implement clinically meaningful management of muscle spasms after spinal cord injury (SCI), and to understand the mechanisms responsible for spasm generation change in response to vibration.

Detailed description

The specific aims of this study are listed below: 1a) Evaluate the ergonomics of the wearable device that will be used to record and detect spasms, then to deliver vibration to tendons to dampen spasms. 1. b) Determine the vibration parameters that best reduce spasms in leg muscles paralyzed by spinal cord injury (SCI) in the laboratory using the wearable device. 2. a) Examine the efficacy of tendon vibration in altering muscle spasms by treating spasms as they occur in real world environments using 24-hour electromyographic (EMG) recordings. Hypothesis 2a: Achilles tendon vibration will dampen spasms acutely, and may alter their distribution Assess excitatory and/or inhibitory mechanisms that underlie spasms, and changes induced with vibration, by recording physiological, clinical, functional and self-reported measures of different aspects of spasticity, and health-related quality of life, before and after conditioning spasms with vibration. These data will provide insight into the site(s), magnitude, and time-course of changes with vibration; and user perspective on the effects of the therapy. Achilles tendon vibration will dampen spasms by reconfiguring circuits generating 6-13 Hz shared drive to motoneurons.

Interventions

DEVICEWearable EMG/Vibration device

The device is a combination of an EMG recorder/detector and a vibrator

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
Shirley Ryan AbilityLab
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Clinical measures of spasticity before, during, and after the intervention will be implemented by an evaluator blind to the treatment effects

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Male and females between ages 18-85 years of age * SCI ( ≥1 month of injury) * ASIA A, B,C and D * SCI above L5 * Able to perform a visible contraction with dorsiflexor and hip flexor muscles (allowing testing of largely impaired patients) * Able to ambulate a few steps with or without an assistive device. Inclusion criteria for healthy controls: * Male and females between ages 18-85 years * Able to complete precision grips with both hands * Able to complete full elbow flexion-extension with both arms. * Able to walk and complete lower-limb tests with both legs.

Exclusion criteria

* Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease, * Any debilitating disease prior to the SCI that caused exercise intolerance * Premorbid, ongoing major depression or psychosis, altered cognitive status * History of head injury or stroke, * Metal plate in skull * History of seizures * Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants. * Pregnant females, and * Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk. This information will be obtained by self-report.

Design outcomes

Primary

MeasureTime frameDescription
Changes in muscle spasms with vibration device4 weeksMeasured by records of EMG from 4 muscles to quantify spasms

Secondary

MeasureTime frameDescription
Questionnaire10 minutesQuantitative and qualitative survey for subjects developed to evaluate comfort and user-friendliness of device. The questionnaire includes 11-point scale questions to rate spasms and effect of the device (0 means no effect and 10 means complete satisfaction. Values for each answer will be interpreted separately and a 10 signifies a better outcome); dichotomous (yes/no) questions about the device, where no signifies no interruption to their different routines and therefore no represents a better outcome; and free-answer questions to collect qualitative data on concerns and recommendations.

Countries

United States

Contacts

Primary ContactMonica Perez, PhD, PT
mperez04@sralab.org312-238-2886

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026